Table 3 Summary of overall results.
Outcome | Result | 95% CI | PI | P value | I2 |
|---|---|---|---|---|---|
ORR | 0.61 | 0.54–0.67 | 0.34–0.85 | 78.5% | |
CR | 0.3 | 0.23–0.36 | 0.08–0.56 | 77.7% | |
OS | 0.35 | 0.29–0.4 | 0.17–0.54 | 65.5% | |
OS in CTs | 1.15 | 0.77–1.77 | 0.24–5.59 | 0.4 | 69.7% |
RR | 0.10 | 0.06–0.15 | 0.00–0.28 | 73.9% | |
RR in CTs (risk ratio) | 0.62 | 0.31–1.25 | 0.11–3.53 | 0.18 | 34.1% |
Skin-ORR | 0.73 | 0.6–0.84 | 70.5% | ||
Gut-ORR | 0.62 | 0.54–0.7 | 59.8% | ||
Liver-ORR | 0.55 | 0.37–0.73 | 71.2% | ||
Heterogeniety Assessment | |||||
Conditioning intensity on ORR “MAC” “nMAC” | 0.59 0.56 | 0.43–0.74 0.51–0.6. | 0.7 | 80% 0% | |
GVHD severity on ORR “Not-advanced” “Advanced” | 0.66 0.51 | 0.57–0.75 0.44–0.57 | 0.006 | 79% 7% | |
Age of recipients on ORR ORR in “Young” ORR in “Old” | 0.64 0.5 | 0.54–0.74 0.41–0.59 | 0.04 | 81% 70% | |
Age of recipients on OS “Young” “Old” | 0.41 0.25 | 0.31–0.50 0.14–0.37 | 0.04 | 81% 70% | |
- MSCs Cell dose on ORR “One” “Two” | 0.59 0.57 | 0.46–0.7 0.52–0.61 | 0.7 | 86% 77% | |
- MSCs frequency on ORR “Frequent” “Infrequent” | 0.64 0.47 | 0.56–0.72 0.34 - o.62 | 0.04 | 79% 77% | |
- MSCs frequency on OS “Frequent” “Infrequent” | 0.4 0.22 | 0.35–0.45 0.17–0.28 | < 0.0001 | 28% 0% | |
- Weekly MSCs IVI on ORR “Once” “Two” | 0.65 0.64 | 0.49–0.8 0.51–0.76 | 0.9 | 87% 89% | |
- MSCs preparation “Cryo” “Fresh” | 0.57 0.65 | 0.48–0.65 0.48–0.8 | 0.4 | 77.7% 82.6% | |
